Novo Nordisk's combination drug for obesity and diabetes shows positive results, heads to phase III
The Danish pharmaceutical firm has successfully concluded a phase II study of a weekly treatment combining two substances, semaglutide and cagrilintide, and is now preparing two phase III programs. (Updated)
by christopher due karlsson, translated by daniel pedersen
In a company press release, Novo Nordisk has announced positive headline results from a phase II trial of a once-weekly treatment, Cagrisema, which combines semaglutide and the amylin analogue cagrilintide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk diabetes drug hit by supply issues
For subscribers
Novo Nordisk has twin successes with once-weekly insulin
For subscribers
